Research programme: SOS1 inhibitors - Satya Pharma
Latest Information Update: 02 Aug 2023
At a glance
- Originator Satya Pharma
- Class Antineoplastics; Small molecules
- Mechanism of Action SOS1 protein inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Colorectal cancer; Non-small cell lung cancer; Pancreatic cancer
Most Recent Events
- 02 Aug 2023 Preclinical trials in Colorectal cancer in India (unspecified route) (Satya Pharma pipeline, August 2023)
- 08 Apr 2022 Preclinical trials in Non-small cell lung cancer in India (PO) (Satya Pharma pipeline, May 2022)
- 08 Apr 2022 Preclinical trials in Pancreatic cancer in India (PO) (Satya Pharma pipeline, May 2022)